Farapulse
Acquired by Boston Scientific
Developing pulsed field ablation technology for cardiac arrhythmia treatment.
Developing pulsed field ablation technology for cardiac arrhythmia treatment.
Sector
Life SciencesCategory
MedtechLocation
Menlo Park, CAInitial Investment
2016Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Farapulse was acquired by Boston Scientific in 2021.
“FARAPULSE is leading a revolution in atrial fibrillation treatment. F-Prime was the first institutional investor to recognize our promise, and played an integral role in our development and ultimate sale to Boston Scientific to bring FARAPULSE technology to patients worldwide.”
Allan Zingeler, CEO
